Jean-Simon Diallo

List of Publications by Year
in descending order

70 papers	3,608 citations	159358 30 h-index	138251 58 g-index
73 all docs	73 docs citations	73 times ranked	3912 citing authors

#	Article	IF	Citations
1	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature, 2011, 477, 99-102.	13.7	459
2	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine, 2018, 10, .	5.8	242
3	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Molecular Therapy, 2012, 20, 749-758.	3.7	231
4	Intelligent Design: Combination Therapy With Oncolytic Viruses. Molecular Therapy, 2010, 18, 251-263.	3.7	177
5	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14981-14986.	3.3	161
6	A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma. Molecular Therapy, 2011, 19, 1913-1922.	3.7	129
7	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine, 2015, 21, 530-536.	15.2	118
8	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	3.2	114
9	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Molecular Therapy, 2010, 18, 888-895.	3.7	109
10	Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms. Frontiers in Microbiology, 2018, 9, 127.	1.5	105
11	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy, 2013, 21, 887-894.	3.7	98
12	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Molecular Therapy, 2010, 18, 1123-1129.	3.7	85
13	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	7.7	77
14	Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. Molecular Therapy, 2018, 26, 56-69.	3.7	77
15	Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. Trends in Cancer, 2015, 1, 266-277.	3.8	73
16	Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Research, 2016, 18, 83.	2.2	73
17	Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine. Molecular Therapy, 2012, 20, 1791-1799.	3.7	70
18	Oncolytic vesicular stomatitis virus expressing interferon-Ïƒ has enhanced therapeutic activity. Molecular Therapy - Oncolytics, 2016, 3, 16001.	2.0	63

#	Article	IF	Citations
19	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. PLoS ONE, 2010, 5, e14462.	1.1	63
20	From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer. PLoS Pathogens, 2014, 10, e1003836.	2.1	61
21	SnapShot: Cancer Immunotherapy with Oncolytic Viruses. Cell, 2019, 176, 1240-1240.e1.	13.5	50
22	Immunotherapy for sarcomas: new frontiers and unveiled opportunities. , 2021, 9, e001580.		48
23	Dimethyl fumarate potentiates oncolytic virotherapy through NF-Î²B inhibition. Science Translational Medicine, 2018, 10, .	5.8	44
24	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nature Communications, 2015, 6, 6410.	5.8	42
25	Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications, 2013, 4, 1974.	5.8	38
26	Propagation, Purification, and In Vivo Testing of Oncolytic Vesicular Stomatitis Virus Strains. Methods in Molecular Biology, 2012, 797, 127-140.	0.4	35
27	Overâ€expression of Î²Bâ€kinaseâ€Îµ (IKKÎµ/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate, 2009, 69, 706-718.	1.2	34
28	Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virotherapy, 2018, Volume 7, 117-128.	6.0	34
29	NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model. Clinical Cancer Research, 2007, 13, 7044-7052.	3.2	32
30	Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma. International Journal of Cancer, 2017, 141, 1257-1264.	2.3	32
31	Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunology Research, 2017, 5, 847-859.	1.6	32
32	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU International, 2007, 100, 303-309.	1.3	31
33	NF-Î²B2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cellular Signalling, 2007, 19, 1093-1100.	1.7	27
34	Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2013, 19, 3832-3843.	3.2	27
35	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. ACS Infectious Diseases, 2018, 4, 1448-1467.	1.8	27
36	Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses. Frontiers in Oncology, 2014, 4, 191.	1.3	26

#	Article	IF	Citations
37	Single-particle characterization of oncolytic vaccinia virus by flow virometry. Vaccine, 2016, 34, 5082-5089.	1.7	26
38	First-in-class small molecule potentiators of cancer virotherapy. Scientific Reports, 2016, 6, 26786.	1.6	25
39	Characterization of Critical Determinants of ACE2â€“SARS CoV-2 RBD Interaction. International Journal of Molecular Sciences, 2021, 22, 2268.	1.8	24
40	Regulation of IÎºB Kinase Îµ Expression by the Androgen Receptor and the Nuclear Factor-ÎºB Transcription Factor in Prostate Cancer. Molecular Cancer Research, 2007, 5, 87-94.	1.5	23
41	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU International, 2008, 101, 1302-1309.	1.3	22
42	Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells. PLoS ONE, 2014, 9, e102365.	1.1	21
43	SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. Biosensors and Bioelectronics, 2021, 180, 113122.	5.3	21
44	Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis. PLoS Pathogens, 2018, 14, e1007264.	2.1	20
45	Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization. Membranes, 2020, 10, 215.	1.4	20
46	Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma. Journal of Virology, 2013, 87, 2363-2366.	1.5	19
47	Exploiting tumor epigenetics to improve oncolytic virotherapy. Frontiers in Genetics, 2013, 4, 184.	1.1	19
48	Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates. BioMetals, 2019, 32, 545-561.	1.8	19
49	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2ÂS for viral entry. Molecular Therapy, 2021, 29, 1984-2000.	3.7	19
50	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate, 2006, 66, 1245-1256.	1.2	17
51	Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. ACS Infectious Diseases, 2021, 7, 3034-3051.	1.8	17
52	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. Molecular Therapy - Oncolytics, 2019, 14, 179-187.	2.0	16
53	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and TÂcell immune response against SARS-CoV-2 infection. Molecular Therapy, 2022, 30, 1885-1896.	3.7	16
54	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nature Communications, 2022, 13, 1898.	5.8	16

#	Article	IF	Citations
55	Ex Vivo Infection of Live Tissue with Oncolytic Viruses. Journal of Visualized Experiments, 2011, , .	0.2	14
56	Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy - Oncolytics, 2021, 20, 306-324.	2.0	12
57	Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus. Virology, 2019, 538, 24-34.	1.1	11
58	The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. Communications Biology, 2020, 3, 254.	2.0	11
59	High-throughput Titration of Luciferase-expressing Recombinant Viruses. Journal of Visualized Experiments, 2014, , 51890.	0.2	10
60	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. BMJ Open, 2020, 10, e034714.	0.8	9
61	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and metaâ€analysis. Hematological Oncology, 2021, 39, 448-464.	0.8	7
62	A novel method of cell embedding for tissue microarrays. Histopathology, 2010, 57, 323-329.	1.6	6
63	Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. Molecular Therapy, 2022, , .	3.7	5
64	Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy. Molecular Therapy - Oncolytics, 2022, 25, 146-159.	2.0	4
65	Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges. , 2019, , 213-246.		2
66	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	1.2	2
67	Influence of pH on the cytotoxic activity of inositol hexakisphosphate (IP6) in prostate cancer. Frontiers in Oncology, 2011, 1, 40.	1.3	1
68	Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy. Molecular Therapy - Oncolytics, 2020, 19, 240-252.	2.0	1
69	Actin-Related Protein 6 (Arp6) Influences Double-Strand Break Repair in Yeast. Applied Microbiology, 2021, 1, 225-238.	0.7	0
70	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. Blood, 2020, 136, 16-16.	0.6	0